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Available online 13 April 2016Aims: Triglycerides droplets are massively stored in muscle in Lipid Storage Myopathies (LSM). We studied in
muscle regulators of lipophagy, the expression of the transcription factor-EB (TFEB) (a master regulator of lyso-
somal biogenesis), andmarkers of autophagywhich are induced by starvation and exert a transcriptional control
on lipid catabolism.
Methods:We investigated the factors that regulate lipophagy in muscle biopsies from 6 patients with different
types of LSM: 2 cases of riboﬂavin-responsivemultiple acyl-CoAdehydrogenase deﬁciency (MADD), 1 case of pri-
mary carnitine deﬁciency (CD), 2 cases of neutral lipid storage myopathy (NLSD-M), 1 case of carnitine–
palmitoyl-transferase-II (CPT) deﬁciency.
Results: Conventional morphology and electronmicroscopy documented the lipid accumulation and its dramatic
resolution after treatment. Muscle immunoﬂuorescence showed that while in MADD and NLSD-M there was a
co-localized expression of TFEB and p62-SQSTM1 (marker of protein aggregates) in some atrophic ﬁbers, in CD
and CPT-II deﬁciency the reactionwas almost normal. In regenerating ﬁbers, TFEB localized in the cytoplasm (in-
active form), whereas in atrophic ﬁbers it localized in the nuclei (active form). Lipid-accumulated/atrophic ﬁbers
did not display p62-positive protein aggregates, indicating, togetherwith the LC3-II (marker of autophagosomes)
and p62-SQSTM1 analysis, that the autophagic ﬂux is often preserved and lipophagy occurs.
Conclusion: In atrophic and regenerating ﬁbers of patients with NLSD-M we observed TFEB over-expression; in
other conditions autophagymarkers are increased, suggesting lipophagy active role on human lipid metabolism.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Lipid storage myopathy
MADD
NLSD-M
Carnitine deﬁciency
TFEB1. Introduction
Lipid Storage Myopathies (LSM) are a group of clinically, biochemi-
cally and genetically heterogeneous disorders characterized by accumu-
lation of lipid droplets in muscle often apposed to mitochondria, with
prevalent limb and neck muscle weakness, sometimes associated with
multisystem dysfunction.
Multiple acyl-CoA dehydrogenase deﬁciency (MADD, MIM#231680)
is caused by defects in electron transfer ﬂavoprotein (ETF), or ETF-ase, adenosine tri-phosphatase;
hrome oxidase; CPT, carnitine-
ole; EMG, electromyography;
rotein; GAPDH, glyceraldehyde
se; LC3, microtubule-associated
,multiple acyl-CoA dehydroge-
TR, nicotinamide adenine dinu-
, neutral lipid storage disease
sporter-2; p62-SQSTM1, p62-
xisome proliferator-activated
e; TFEB, transcription factor-EB.
ent, Fondazione San Camillo
).
. This is an open access article underdehydrogenase (ETF-DH) [1,2], two mitochondrial enzymes. The clinical
phenotype in late-onset patients consists in proximalmyopathy, high cre-
atine kinase (CK) levels, lethargy, vomiting, hypoglycemia, metabolic aci-
dosis, hepatomegaly, glutaric aciduria during crises, and lipid storage in
muscle. The diagnosis is suggested by the acyl-carnitine proﬁle and uri-
nary organic acids, revealing low serum free carnitine but elevated acyl-
carnitines. The disease is responsive to treatment with riboﬂavin as well
as carnitine supplementation.
Neutral lipid storage disease with myopathy (NLSD-M, MIM#
610717) is characterized by slowly progressive proximal muscle weak-
ness affecting the upper and lower limbs,with increased CK levels, cardio-
myopathy, diabetes mellitus, hepatic steatosis, and hypertriglyceridemia.
Leukocytes show a characteristic accumulation in cytoplasm of triglycer-
ides called “Jordan's anomaly”. The disease is due to PNPLA2 gene muta-
tions [3], causing a defect in the adipose triglyceride lipase (ATGL),
which catalyzes the initial step in the breakdownof intracellular triglycer-
ides (lipolysis), and as a treatment only medium chain triglycerides ap-
pear promising.
Carnitine deﬁciency (CD, MIM#212140) is a potentially lethal but
very treatable disorder which is due to a defect in the carnitine organic
cation transporter (OCTN2), which results in impaired fatty acid oxida-
tion in striated muscle. CD is clinically characterized by carnitine-the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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hypoketotic coma, or acute hepatic failure such as Reye's syndrome,
with very low plasma carnitine content and severe renal leak of carni-
tine. Primary CD has to be differentiated by secondary carnitine deﬁ-
ciency status that occurs in MADD.
The deﬁciency of carnitine–palmitoyl-transferase-II (CPT-II), an en-
zyme involved in the transport of fatty acids into themitochondrial ma-
trix, is clinically characterized by recurrent myoglobinuric attacks
(MIM#255110) triggered by risk factors such as exercise, fasting,
fever, and infection, which may be complicated by acute renal failure
and respiratory failure.
While triglycerides aremassively stored inMADD andNLSD-M, lipid
droplets are almost absent in CPT-II deﬁciency. The reason for this mor-
phological difference is unknown.
Autophagy, a lysosomal-dependent catabolic process, is generally
activated during starvation and plays a central role in lipid metabolism,
i.e. lipophagy, because it shuttles lipid droplets to the lysosomeor tomi-
tochondria,where they are degraded or oxidized. The Transcription Fac-
tor EB (TFEB), amaster regulator of lysosomal biogenesis and autophagy
[4], is induced by starvation through an auto-regulatory feedback loop
and exerts a transcriptional control of genes involved in lipid catabolism
and indirectly in the transport of fatty acid chains across themembrane,
and the beta-oxidation of fatty acids inmitochondria, via nuclear perox-
isome proliferator-activated receptor-γ-coactivator-1α (PPARα) and of
its co-activator PGC1α [5]. Inactive TFEB resides in the cytoplasmwhen
it is phosphorylated by mTORC1, and after de-phosphorylation it trans-
locates to the nucleus during starvation [6,7], where it induces its ex-
pression as active form and initiates the metabolic shift of the
catabolism of lipids. Therefore, TFEB over-expression is known to pro-
mote lysosome expansion and autophagy [8,4].
Recent advances have been made using PPARγ agonist treatment
(i.e. bezaﬁbrate), with beneﬁt in ﬁbroblasts of CPT-II deﬁciency but
without consistent effects at clinical levels [9–11].
We investigate the factors that regulate fatty acid degradation and
lipophagy in muscle from patients with LSM of different etiology. The
autophagic ﬂux and its possible impairment was monitored by the ex-
pression of LC3 and p62-SQSTM1-containing protein aggregates.2. Materials and methods
2.1. Patients' selection criteria
For this study we selected 6 patients (4 females, 2 males), including
5 cases with LSM of different etiology (2MADD, 1 CD, 2 NLSD-M) and 1
case with CPT-II deﬁciency (Table 1).Table 1
Clinical data, laboratory ﬁndings, and treatment.
Patient,
gender
Diagnosis Age at
biopsy
(years)
Age at
onset
(years)
Main clinical features Causes of
metabolic
1, F MADD 41 38 Respiratory insufﬁciency, proximal
weakness, unable to walk, acute
quadriplegia
Poor nutri
2, F MADD 35 35 Waddling gait, hypotonia, epilepsy,
dysphagia, psychosis
Poor nutri
alcoholism
lactacidem
3, F CD 36 7 Muscle weakness, difﬁculty walking,
weight loss
Poor nutri
4, F NLSD-M 39 18 Muscle weakness and atrophy,
difﬁculty walking, hepatomegaly
Diabetes
5, M NLSD-M 71 66 Muscle weakness, dropped head
syndrome
Diabetes
6, M CPT-II
deﬁciency
36 17 Recurrent exertional myoglobinuria,
acute renal failure
Muscle exe
N.d.: not determined.
⁎ Values are expressed as nanomoles/mg protein. Normal values: 10.5–29.5 nmol/mg protei2.2. Muscle morphology and biochemical analyses
Muscle biopsies, which were performed following written consent
(according to ethical standards approved by University of Padova) was
obtained as part of the diagnostic process,were frozen in liquid nitrogen
and stored at−80°. Cryostat-cut sections 10 μm thickwere used to per-
form a panel of routine stains, including hematoxylin–eosin, Gomori
trichrome, Oil-Red-O, PAS, NADH-TR, COX, SDH, ATP-ases, acid phos-
phatase. Muscle morphology was evaluated by conventional optic
examination.
For electron microscopy analysis, freshmuscle tissues were routine-
ly processed and examined with a Philips 400T transmission electron
microscope. Two biopsies of Patient 1 were examined, before and after
treatment.
Muscle homogenates were used to determine the content of total
carnitine and acyl-carnitines, and the activity of mitochondrial en-
zymes, using conventional radiochemical or spectrophotometric assays,
respectively.
2.3. Immunohistochemical analysis
To investigate the expression of TFEB and p62-SQSTM1 (marker
of protein aggregates) in muscle ﬁbers, serial muscle sections (6–
8 μm thick) were ﬁxed with 4% paraformaldehyde, treated with
0.1% Triton, blocked in 0.5% albumin + 10% horse serum, and incu-
bated overnight at 4 °C with the following primary antibodies: p62-
SQSTM1 (GP62-C, Progen Biotechnik, Heidelberg, Germany), TFEB
(MBS120432, MyBioSource, San Diego, CA), and developmental
myosin heavy chain (marker of regeneration) (MONX10806,
Monosan, Uden, The Netherlands) [12]. Appropriate secondary
ﬂuorescent antibodies (Alexa-Fluor, Invitrogen, Paisley, UK) were
used. Slides were mounted using Vectashield medium with DAPI
stain (Vector, Burlingame, CA) and examined by ﬂuorescence
microscopy.
2.4. Immunoblot analysis
To investigate the expression of p62-SQSTM1 and LC3 (marker of
autophagosome proliferation) by semi-quantitative immunoblot analy-
sis, muscle sections were lysed in Laemmli buffer, proteins were re-
solved by polyacrylamide gel electrophoresis, and immunoblotted
using the following primary antibodies: LC3 (L7543, Sigma-Aldrich, St.
Louis, MO), p62-SQSTM1 (GP62-C, Progen), TFEB (4240, Cell Signaling,
Milan, Italy), GAPDH-glyceraldehyde 3-phosphate dehydrogenase
(8245, Abcam, Cambridge, UK) [12]. Only using LC3 immunoblotting,
the LC3-II band (corresponding to LC3 linked to membranes andstress
Muscle
carnitine
level⁎
Mitochondrial respiratory
chain enzyme activity
Treatment
tion 3.88
(17%)
Complex I (65%), complex II + III
(30%), complex II (46%), complex
IV (61%)
Riboﬂavin (200 mg/day),
carnitine (4 g/day), MCT oil
tion,
,
ia
2.27
(11%)
Complex IV (16%), complex II + III
(25%)
Riboﬂavin (200 mg/day),
carnitine (4 g/day),
carbamazepine
tion 0.81
(5%)
Complex IV (25%) Carnitine (4 g/day), MCT oil
8.5
(54%)
N.d. Dietary, MCT oil
11.3
(73%)
Normal activity Dietary, MCT oil
rcise N.d. N.d. Dietary, MCT oil, avoiding
triggering factors
n. In brackets is indicated the percentage of control mean.
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measured from that corresponding to LC3-I (the cytosolic component
not linked to autophagosomes). Immunolabeling was visualized using
the chemiluminescent substrate (GE Healthcare, Milan, Italy). The ex-
pression levels of p62-SQSTM1 and LC3-II bands were determined by
densitometric quantiﬁcation using the ImageJ software (US National In-
stitutes of Health) and normalized to GAPDH band.Fig. 1.Muscle morphology and electron microscopy of patient 1 (a–c), patient 2 (d–f), patient
(a,d,g,j,m) showed vacuolar myopathy involving many ﬁbers, with pronounced cytoplasmic
(h) stains. Note that in patient 1, themassive lipid deposition observed in theﬁrst biopsy (a,b)w
ofmuscle (f,i,o) showed lipid droplet depositionwithoutmitochondrial disruption. Giemsa stain3. Results
3.1. Case reports (Table 1)
3.1.1. Patient 1 (MADD)
At 38 years of age, this woman complained of acute weakness of
upper girdle muscle, neck ﬂexors and respiratory muscles, and she3 (g–i), patient 4 (j,k), patient 5 (m–o). Muscle sections stained with hematoxylin–eosin
accumulation of neutral lipids, as documented by Oil-Red-O (b,c,e,k,n) or Sudan Black B
as signiﬁcantly reduced after treatment in a secondbiopsy (c). Ultrastructural examination
of leukocytes from patient 5 (l) showed lipid vacuoles corresponding to Jordan's anomaly.
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2277 U/L, EMG was myopathic. She was hospitalized in an intensive
care unit for acute respiratory infection, where she was tracheotomised
and remained for over 3 weeks. A ﬁrst quadriceps femoris muscle
biopsy showed massive lipid storage (Fig. 1) and, on electron mi-
croscopy, a number of swollen and abnormal mitochondria (Fig.
2). Biochemically, a secondary carnitine-deﬁciency consistent with
MADD was found: elevated levels of medium and long chain acyl-
carnitines in plasma (Table 1); mitochondrial enzymes were vari-
ably reduced including citrate synthase (Table 1). Treatment with
low-fat and high-protein diet directed to prevent autophagy, medi-
um chain triglycerides (MCT) oil (which enters directly into mito-
chondria) and 4 g of carnitine produced a fast improvement and
normalization of carnitine in plasma and inmuscle of a second biop-
sy on deltoid muscle. We observed a dramatic recovery of myoﬁber
structure with decreased lipid droplets. Riboﬂavin supplementation
(200 mg/day) also produced subsequent marked improvement,
preventing further metabolic crises.3.1.2. Patient 2 (MADD)
At 36 years of age this woman was hospitalized for psychosis, alco-
holism and poor nutrition, she had muscle pain in upper limbs, weak-
ness in lower limbs, difﬁculty walking and raising from a chair, was
unable to raise from the ﬂoor and climb stairs. CK was 868 U/L andFig. 2.Muscle electronmicroscopy of patient 1 before (A–D) and after (E, F) treatment. Note tha
mitochondria (A–C) and diffuse lysis ofmyoﬁbrils (D). In the secondbiopsy there is a complete r
are present (F).EMG was myopathic. She had increased plasma acyl-carnitines and
glutaric aciduria was diagnosed. Quadriceps femoris muscle biopsy re-
vealed LSM (Fig. 1), low muscle carnitine content with increased acyl-
carnitines, and reduced activity of mitochondrial OXPHOS complex en-
zymes (Table 1). Treatment with low-fat, high-protein diet and 4 g/day
carnitine produced some improvement; however, only riboﬂavin sup-
plements (200 mg/day) produced marked clinical improvement. At
age 45 years she presented pneumonia ab ingestis with septic shock,
metabolic acidosis, dysphagia and respiratory insufﬁciency which re-
quired tracheostomy and assisted ventilation. She slowly improved
with riboﬂavin, and carnitine treatment, which she had previously
abandoned.3.1.3. Patient 3 (CD)
At 7 years of age, this girl had difﬁculty climbing stairs, waddling gait
and elevated CK levels. She was hospitalized at age 10 for apparently
unexplained anorexia, weight loss and increased weakness. She was
not unusually thin or frail but had Gowers sign, weakness of neck mus-
cles, triceps, scapular rotator, ileopsoas, thigh abductors, and was un-
able to raise arms. EMG was myogenic. CK was normal. Quadriceps
femoris muscle biopsy showed lipid droplet accumulation (Fig. 1)
which was responsive to carnitine supplementation. She had low mus-
cle carnitine levels (Table 1). Measurement of respiratory chain en-
zymes activity showed reduced complex IV activity (Table 1). Thet in theﬁrst biopsy there are a number of lipid droplets surrounded by a number of swollen
ecovery of themuscle structure,where only fewabnormalmitochondria (E) and few lipids
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[13].
3.1.4. Patient 4 (NLSD-M)
This 44-year-old woman of Iranian origin was born from consan-
guineous parents. She complained of early fatigability since late teens
with increasing difﬁculties in running andwalking. After age 30, she de-
veloped a progressive weakness in both girdles. CK was 1200 U/L, EMG
was myopathic. She had hepatomegaly and marked fatty liver on ultra-
sound exam. Laboratory tests revealed increased plasma levels of
glucose, total triglycerides and VLDL. No ichthyosis or cataracts was re-
ported. There was no clinical or instrumental signs of cardiac involve-
ment. She was found to be homozygous carrier for apoE2 allele and
developed type 2 diabetes. Biceps brachii muscle biopsy showed LSM
(Fig. 1) with reduced muscle carnitine content (Table 1). She had a ho-
mozygous frame-shift mutation (c.695delT, p.L255X) in the PNPLA2
gene [14].
3.1.5. Patient 5 (NLSD-M)
This 79-year-old man had progressive muscle weakness in the arms
and dropped head since the age of 66. At 70 years of age, he complained
of cervical pain and received radiation therapy to the upper limbs. CK
level was 330 U/L. EMGwas neurogenic. Quadriceps femoris muscle bi-
opsy showed LSM (Fig. 1) with only slightly reduced muscle carnitine
content and normalmitochondrial enzymes (Table 1). Jordan's anomaly
was found in leukocytes (Fig. 1). At age 75, he presented increased
weakness in biceps and ﬁnger extensors, had anterocollis, kyphosis, bi-
lateral pes cavus, and atrophy of the pectoralmuscles, andwasunable to
lift arms over the head. At age 77, he developed diabetes mellitus. No
ichthyosis or cataracts was reported. There was no clinical or instru-
mental signs of cardiac involvement. He has a homozygous missense
mutation in the PNPLA2 gene (c.570ANC, p.S191R) [15].Fig. 3. Immunohistochemical analysis. Serial sections from muscle biopsy of Patient 2 (A–
immunolabeled for TFEB (B,F,J, in red), p62-SQSTM1 (C,G,K, in green), TFEB/p62-SQSTM1 (D
DAPI (blue). Note that in some atrophic-vacuolated ﬁbers displayed increased TFEB localizatio
whereas there is an evident co-localized over-expression of p62-SQSTM1 and TFEB in the cyto3.1.6. Patient 6 (CPT-II)
This man was born from consanguineous parents and has a brother
similarly affected. At age 17 years, after intense exercise, the patient had
severe asthenia in lower limbs, painful cramps in calf muscles and
myoglobinuria. CK was 997 U/L. In the following years he presented re-
current myoglobinuric episodes with renal insufﬁciency, triggered by
muscle exercise. At 36 years a neurological examination was normal.
Quadriceps femoris muscle biopsy showed myopathic changes with
few and thin lipid droplets accumulation, and deﬁcient CPT activity.
He was homozygous for the common missense mutation in the CPT2
gene (c.338CNT, p.S113L).3.2. Muscle morphology, immunohistochemistry and western blotting
Muscle biopsies showed pronounced lipid storage in 5 of the 6 cho-
sen patients (Table 1, Fig. 1), whereas in the CPT-II deﬁcient patient
there where only thin and sparse lipid droplets.
In two consecutive biopsies of Patient 1 before and after treatment
we documented disappearance of lipid storage (Fig. 2).
Immunoﬂuorescence study revealed in several cases the presence of
atrophic and lipid-accumulated ﬁbers which also displayed increased
nuclear TFEB localization and accumulation of p62-SQSTM1-positive in-
clusions. While in patients 2 (MADD), 4 and 5 (NLSD-M) there was an
evident co-localized over-expression of p62-SQSTM1 and TFEB in
some atrophic ﬁbers (Fig. 3), in patients 3 (CD) and 6 (CPT-II deﬁciency)
the reaction appeared normal (Supplemental Figs. 1, 2, 3). Interestingly,
in regenerating ﬁbers, TFEB localized in the cytoplasm, whereas in atro-
phic and lipid-accumulated ﬁbers it localized in the nuclei (Fig. 3). Most
of these latter ﬁbers did not showp62-positive protein aggregates, indi-
cating that the autophagic ﬂux was still preserved.
The autophagic activity, whichwas clearly active using LC3 and p62-
SQSTM1 in at least 4 of our patients, is likely to be due to the fact that theD), Patient 5 (E–H) and Patient 4 (L–M) stained with hematoxylin–eosin (A,E,L), and
,H,L, merged), developmental myosin heavy chain (M). Nuclei are counterstained with
n in the nuclei and cytoplasmic accumulation of p62-SQSTM1-positive inclusions (B–D),
plasm of atrophic ﬁbers undergoing regeneration (J–M).
Table 2
Differential molecular and biochemical pathways regulation in various LMS.
Normal condition MADD NLSD-M Carnitine deﬁciency CPT deﬁciency
Lipolysis and lipophagy are
active only during starvation
Lipolysis and lipophagy
are increased
Due to ATGL deﬁciency,
lipolysis is impaired,
lipophagy is active
Normal lipolysis and lipophagy Normal lipolysis
and lipophagy
Normal carnitine Low carnitine Normal carnitine Low carnitine Normal carnitine
Low acyl-carnitines Increased acyl-carnitines Low acyl-carnitines Low acyl-carnitines Increased acyl-carnitines
No glutaric aciduria Gutaric aciduria No glutaric aciduria No glutaric aciduria No glutaric aciduria
Normal mitochondria Decreased mitochondria
(palmitate oxidation)
Decreased mitochondria Normal mitochondria Normal mitochondria
Free diet Treatment with riboﬂavin and carnitine Free diet Carnitine Bezaﬁbrate (?)
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lipophagy and lipolysis. Evidence of autophagic activity was found by
both immunohistochemistry and western blotting in NLSD-M and
MADD but not in patients with CD or CPT-II deﬁciency (Table 2).
On LC3 and p62 immunoblotting (Fig. 4), patients 1,2,4,5 (MADD or
NLSD-M) showed a markedly increased LC3-II band (marker of
autophagosome proliferation), which was associated with an increased
p62-SQSTM1 band in patients 1 and 4, suggesting a block in the autoph-
agic ﬂux. TFEB immunoblotting showed variable levels, with higher ex-
pression in patients 1 and 5 (Fig. 4).4. Discussion
Here we report the ﬁrst ultrastructural and morphological evidence
of lipid droplet decrease in two patients with riboﬂavin-responsive
MADD. We think that both lipophagy, TFEB and autophagosomes are
linked in a critical regulatory role of lipid droplets in MADD. Until re-
cently, autophagy regulation was thought to occur by accumulation of
LC3-II in response to autophagic stimulus. We observed that in human
biopsies, TFEB activation was present both in cytoplasm and in nucleus
and that LC3-II increase was seen both associated to p62 accumulation.
Therefore, the accumulation of lipid droplets in humanmuscle provokes
adaptative lipophagic reaction.
The combustion of lipid droplets for energy begins with the ac-
tion of lipases on the lipid droplets monolayer. Recently, however,
lipophagy has been implicated in neutral lipid utilization from lipid
droplets. The mechanism by which lipophagy is regulated requires
TFEB activation.
Patients 1 and 5 had important lipophagy impairment (increased
LC3-II), and they showed also the higher levels of TFEB inmuscle. There-
fore, lipophagy impairment and TFEB increase corresponds to p62-
positive inclusions and in themost severemuscle impairment at clinical
level and consequent muscle atrophy. Lipophagy impairment results in
p62-aggregates in myoﬁbers and may reﬂect the impairment of the lastFig. 4. Immunoblot analysis of p62-SQSTM1, LC3, TFEB, and the loading control protein
GAPDH in one control muscle (C) and the 6 LSM patients (1–6). Note that patients 1,4,5,2
(MADD and NLSD-M) displayed increased LC3-II band (marker of autophagosome
proliferation), and that some of them showed also an increased p62 band, suggesting a
block in the autophagic ﬂux.chance to mobilize fatty acids from lipid droplets to give energy to
mitochondria.
The phenotypic consequences of TFEB over-expression in muscle ﬁ-
bers are striking and consist in reduced size, and presence of p62-
positive protein aggregates. It is well known that the inhibition of au-
tophagy in muscle was proposed to cause ﬁber atrophy [16]. Our data
agree with such experimental data suggesting that autophagy might
exert a positive role in lipid metabolism to decrease lipid accumulation.
In NLSD-M the accumulated lipid droplets are hydrolyzed by three
different lipases: the lipid droplet-associated adipose triglyceride lipase
(ATGL), which is primarily defective, and the cytosolic hormone-
sensitive lipase (HSL) and themonoacyl-glycerol lipase, which are pres-
ent but not adequate to perform lipolysis. In our NLSD-M cases we ob-
served LC3-II over-expression, which was consistent with activation of
autophagy, and was also associated in some cases with p62 over-
expression (block of lipophagy). Inmuscle biopsy from twoNLSD-Mpa-
tients we observed TFEB over-expression, which might have a role in
autophagy induction. In 4 LSM cases we documented lipophagy activa-
tion, which was probably consequent to lipid droplets increase.
To sustain cell metabolism, lipid droplets have to be degraded to re-
lease fatty acids, and this may be triggered by nutrient deprivation. Sev-
eral molecules facilitate the cellular import of fatty acids including the
plasma membrane OCTN2 translocase. Once in the cytosol, fatty acids
are esteriﬁed to CoA and then conjugated to carnitine by CPT-I and
imported by CPT-II.
The expression and activity of enzymes involved in lipid catabolism
are tightly regulated by transcriptional and post-transcriptional mecha-
nisms, themain of which involve the activities of PPARα and PGC1α in-
duced during fasting.
Increasing evidence supports the role by the nutrient-sensitive TFEB
and other members of the FOXO family in regulating lipophagy during
fasting; PPARα and PGC1α might link lipophagy to other factors in-
volved in lipid catabolism.
The way in which lipophagy is variably regulated inMADD versus
NLSD-M is intriguing, and it is puzzling to understand how TFEB and
p62 are activated in these two conditions, since the efﬁcacy of lipol-
ysis might differ. On the contrary, in CPT-II deﬁciency and CD we did
not observe activation of either pathways, and we found neither
autophagosomes nor p62-protein aggregates.
ATGL, which is the key enzyme in the ﬁrst step of lipid degradation
in muscle, provides a fatty acid moiety that can be used for regulating
transcriptional response and mitochondrio-genesis. On the contrary,
in CD and CPT-II deﬁciency there must be a way to circumvent themet-
abolic derangementwithout recurring to lipophagy. In fact, in CPT-II de-
ﬁcient muscle there is only slight atrophy, and occasional regenerating
ﬁbers only after rhabdomyolysis.
Wemight speculate that TFEB activationmight be a new therapeutic
target to avoid deterioration in LSM, but we know from animal models
that TFEB up-regulation could be extremely toxic [17]. Our study in
MADD patients conﬁrmed the sensitivity of beta-oxidation pathway.
Lipophagy occurs in-vivo during exercise or starvation, since auto-
phagosomes sequester portions of lipid droplets and target them to ly-
sosomes for degradation. It has been suggested that intracellular
1373C. Angelini et al. / Biochimica et Biophysica Acta 1862 (2016) 1367–1373accumulation of lipid droplets may promote autophagy, because lipids
provide precursors for the nascent autophagosome membrane. In
ATGL deﬁciency, which function is to mobilize triglycerides to form
di-acyl-glycerol, triglycerides could be used to build the phospholipids
necessary for membrane formation. In NLSD-M ATGL is defective, and
the lysosomal protein aggregates might cause atrophy.
Increasing evidence suggests that TFEB and p62 regulate lipophagy
during several physiological conditions, including exercise and fasting
[18]. PPARα and PGC1α link lipophagy to other pathways involved in
lipid catabolism (i.e. lipolysis) [19]; therefore, a number of factors coor-
dinate lipid degradation pathways in muscle. Autophagy pathways rely
on the activity of various organelles: autophagosomes, endoplasmic re-
ticulum and lysosomes. The process by which lipid catabolic pathways
link to other lipid oxidative pathways are still under investigation; how-
ever, lipophagy and lipolysis must be co-regulated to optimize lipid use
and prevent excessive accumulation of lipids, and avoid damage to
myoﬁbers. Four of our patients, twowith ATGL deﬁciency, displayed in-
creased levels of LC3-II and also p62-positive protein aggregation, possi-
bly suggesting that autophagy might have been activated and
subsequently inhibited [20,12]. Therefore, the physio-pathological role
of such signaling mechanism would contribute to the development of
these pathological conditions (Table 2).
It is likely that the role of lipolytic process is directed to avoid the
toxicity of fatty acid accumulation on mitochondrial function. Most of
our patients were studied during ametabolic crisis provoked by periods
of fasting; one MADD patient was initially in deep distress and then re-
covered, and the other MADD patient had multiple causes of metabolic
stress (including malnutrition and alcoholism). The two NLSD-M pa-
tients had progressive weakness, diabetes, and abnormal hydrolysis of
triglyceride storage that requires indeed the ATGL lipase.
Given that during lipolysis intracellular lipid droplets are degraded
to fatty acids, one could wonder how fatty acids are continuously deliv-
ered tomitochondria. In humans, it is clear that fatty acid trafﬁcking de-
pends from lipid droplets lipolysis but lipophagy is also needed [21].We
consider that in the patientswe studied, both of these two different pro-
cesses are at play: lipophagy, which is due to autophagic digestion of
lipid droplets is mainly required in catabolic states; lipolysis, where cy-
toplasmic lipases directly hydrolyze triacylglycerol from lipid droplets,
subsequently providing energy. The ATGL mechanism is ﬁnely regulat-
ed, and the fatty acids move directly from lipid droplets into mitochon-
dria. In our MADD patients, an increased autophagic activity was
suggested by western blotting results, while in NLSD-M patients, fatty
acids ﬂux into mitochondria seemed to be impaired as well as endoge-
nous lipid droplet lipolysis, although some evidence of lipophagy was
also seen.
It is worth noting that these metabolic conditions can be reversible,
since the elimination of lipid droplets can be obtained either by riboﬂa-
vin treatment, or by using medium-chain triglycerides, that directly go
to mitochondria as a fuel. In all our patients, risk factors, such as poor
nutrition, precipitated their catabolic state. Avoiding such risk factors
is an important part of clinical management.
5. Conclusions
This is a pilot study on three different disorders of lipid metabolism,
whichwere studied onmusclewithmarkers of lipophagy. In two condi-
tions (MADD and NLSD-M) there was an activation of p62/SQSTM1 and
LC3-II.
Further studies are required to understandwhether ATGL-mediated
fat catabolism might regulate mitochondrial complexes and energy
production.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2016.04.008.Transparency document
The Transparency document associated with this article can be
found, in online version.
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